"alpha 1-Antitrypsin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Plasma glycoprotein member of the serpin superfamily which inhibits TRYPSIN; NEUTROPHIL ELASTASE; and other PROTEOLYTIC ENZYMES.
| Descriptor ID |
D000515
|
| MeSH Number(s) |
D12.644.861.035 D12.776.124.050.070 D12.776.124.790.106.085 D12.776.377.715.085.085 D12.776.395.068 D12.776.872.035
|
| Concept/Terms |
alpha 1-Antitrypsin- alpha 1-Antitrypsin
- alpha 1 Antitrypsin
- alpha 1 Antiprotease
- Antiprotease, alpha 1
- Serpin A1
- alpha 1-Protease Inhibitor
- Inhibitor, alpha 1-Protease
- alpha 1 Protease Inhibitor
- alpha 1-Proteinase Inhibitor
- Inhibitor, alpha 1-Proteinase
- alpha 1 Proteinase Inhibitor
- Trypsin Inhibitor, alpha 1-Antitrypsin
- Trypsin Inhibitor, alpha 1 Antitrypsin
- A1PI
- alpha 1-Antiproteinase
- 1-Antiproteinase, alpha
- alpha 1 Antiproteinase
|
Below are MeSH descriptors whose meaning is more general than "alpha 1-Antitrypsin".
Below are MeSH descriptors whose meaning is more specific than "alpha 1-Antitrypsin".
This graph shows the total number of publications written about "alpha 1-Antitrypsin" by people in this website by year, and whether "alpha 1-Antitrypsin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2015 | 2 | 1 | 3 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "alpha 1-Antitrypsin" by people in Profiles.
-
Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry. Int J Chron Obstruct Pulmon Dis. 2020; 15:3193-3199.
-
Alpha-1 antitrypsin suppresses macrophage activation and promotes islet graft survival after intrahepatic islet transplantation. Am J Transplant. 2021 05; 21(5):1713-1724.
-
Overexpression of alpha-1 antitrypsin in mesenchymal stromal cells improves their intrinsic biological properties and therapeutic effects in nonobese diabetic mice. Stem Cells Transl Med. 2021 02; 10(2):320-331.
-
Clathrin-mediated Endocytosis of Alpha-1 Antitrypsin is Essential for its Protective Function in Islet Cell Survival. Theranostics. 2019; 9(13):3940-3951.
-
Sequencing Alpha-1 MZ Individuals Shows Frequent Biallelic Mutations. Pulm Med. 2018; 2018:2836389.
-
Anti-Proteases and Alpha-1 Antitrypsin Augmentation Therapy. Respir Care. 2018 Jun; 63(6):690-698.
-
Impact of HIV infection on a1-antitrypsin in the lung. Am J Physiol Lung Cell Mol Physiol. 2018 04 01; 314(4):L583-L592.
-
COPD in individuals with the PiMZ alpha-1 antitrypsin genotype. Eur Respir Rev. 2017 Dec 31; 26(146).
-
a-1 Antitrypsin Enhances Islet Engraftment by Suppression of Instant Blood-Mediated Inflammatory Reaction. Diabetes. 2017 04; 66(4):970-980.
-
Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):227-33.